Plus Therapeutics (NASDAQ:PSTV) Releases Earnings Results

Plus Therapeutics (NASDAQ:PSTV) issued its quarterly earnings results on Thursday. The company reported $0.25 earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $1.37 million for the quarter.

Plus Therapeutics Stock Down 5.8%

Shares of NASDAQ:PSTV traded down $0.02 during midday trading on Thursday, reaching $0.29. 3,668,059 shares of the company traded hands, compared to its average volume of 11,006,773. The firm’s fifty day moving average price is $0.32 and its two-hundred day moving average price is $0.48. The firm has a market capitalization of $40.28 million, a price-to-earnings ratio of -0.15 and a beta of 0.79. Plus Therapeutics has a 12 month low of $0.16 and a 12 month high of $2.08.

Institutional Investors Weigh In On Plus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of PSTV. Susquehanna International Group LLP bought a new position in shares of Plus Therapeutics in the third quarter valued at approximately $46,000. Jane Street Group LLC bought a new position in Plus Therapeutics in the 2nd quarter valued at $41,000. Scientech Research LLC bought a new position in Plus Therapeutics in the 3rd quarter valued at $100,000. XTX Topco Ltd purchased a new position in shares of Plus Therapeutics during the 4th quarter valued at $127,000. Finally, State Street Corp increased its holdings in shares of Plus Therapeutics by 37.1% in the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after purchasing an additional 127,000 shares during the period. 3.28% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on PSTV. HC Wainwright reissued a “buy” rating and set a $1.00 price objective (down from $2.00) on shares of Plus Therapeutics in a report on Friday, January 23rd. Lake Street Capital started coverage on Plus Therapeutics in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $2.00 target price on the stock. Ascendiant Capital Markets cut their price target on Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, November 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a report on Thursday, January 22nd. Finally, D. Boral Capital dropped their price objective on shares of Plus Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, January 22nd. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Plus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $5.80.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.